Pioglitazone

SKU: orb1310828

Description

Pioglitazone is a potent and selective PPARγ agonist with EC50 values of 0.93 μM (human) and 0.99 μM (mouse). This orally active small molecule is widely used in diabetes research for in vitro mechanistic studies and in vivo models of insulin resistance and glucose homeostasis.

Research Area

Cell Biology, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery

Images & Validation

−

Key Properties

−

CAS Number	111025-46-8
MW	356.44
Purity	95.00% (May vary between batches)
Formula	C₁₉H₂₀N₂O₃S
SMILES	C(C1C(=O)NC(=O)S1)C2=CC=C(OCCC3=CC=C(CC)C=N3)C=C2
Target	PPAR,Ferroptosis
Solubility	10% DMSO+90% Corn Oil:2 mg/mL (5.61 mM);DMSO:28.8 mg/mL (80.8 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

−

Target IC50	PPARδ (human):43 μM (EC50)\|PPARγ (mouse):0.99 μM (EC50)\|PPARα (mouse):100 μM (EC50)\|PPARα (human):100 μM (EC50)\|PPARγ (human):0.93 μM (EC50)
In Vivo	METHODS: To investigate the effect of Pioglitazone on insulin resistance, Pioglitazone (10 and 30 mg/kg) was orally administered to ob/ob and adipo-/-ob/ob mice once daily for 14 days. RESULTS: Pioglitazone improves insulin resistance and diabetes, which may be lipocalin-dependent in the liver but not in skeletal muscle. METHODS: To investigate the effect of Pioglitazone on cardiac remodeling, diabetic nephropathy rats were treated with oral administration of Pioglitazone (10 mg/kg) once daily for 4 weeks. RESULTS: Pioglitazone significantly reduced body weight (BW), cardiac hypertrophy, elevated blood glucose levels, and related dyslipidemia.
In Vitro	METHODS: HT-1080, MDA-MB-231, and PC-3 cells were treated with Pioglitazone for 3 days, and target cell toxicity was measured using MTT assay. RESULTS: Pioglitazone did not affect cell growth at 100 μM.

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Pioglitazone, PPARγ, PPAR, Peroxisome proliferator-activated receptors, U72107, U-72107, U 72107, inhibit, ligand-binding, Ferroptosis, Inhibitor, diabete, domain, blood glucose

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

4829 ↗

Key Properties

−

No computed properties available.

Protocol Information

Find More Protocols

CAS Number:	1266523-09-4
MW:	394.53
Formula:	C₁₉H₁₉KN₂O₃S

Purity:	>98%
CAS Number:	112529-15-4
MW:	392.9
Formula:	C₁₉H₂₀N₂O₃S ∙ HCl

CAS Number:	146062-45-5
MW:	370.42
Formula:	C₁₉H₁₈N₂O₄S

CAS Number:	146062-46-6
MW:	408.90
Formula:	C₁₉H₂₁ClN₂O₄S

CAS Number:	959687-65-1
MW:	356.44
Formula:	C₁₉H₂₀N₂O₃S

Pioglitazone

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Pioglitazone potassium [orb1688201]

Pioglitazone HCl [orb1310827]

Ketopioglitazone [orb1705620]

Leriglitazone hydrochloride [orb1983413]

(R)-Pioglitazone [orb2564261]

Quality Guarantee

Compound Identifiers

Key Properties

Protocol Information

Available Sizes

Email

UK Office

US Office

CN Office

Distributors